Private Practice
Jun 29, 2025
F90 Attention-Deficit/Hyperactivity Disorder (ADHD): Comprehensive Guide for Mental Health Professionals

Brayden Efseroff, MD

Allia Team
Understand ADHD: A comprehensive guide for mental health professionals on ICD-10 code F90, covering diagnosis, symptoms, treatment, and patient resources for Attention-Deficit/Hyperactivity Disorder.
Want to see it yourself?
Quick Reference
Code: F90 (with 4th character specifications)
Disorder: Attention-Deficit/Hyperactivity Disorder (ADHD)
Category: Neurodevelopmental Disorders
Billing Status: Active code for reimbursement (requires 4th character)
DSM-5 Equivalent: 314.0x (Attention-Deficit/Hyperactivity Disorder)
Common Comorbidities: Learning Disorders, Oppositional Defiant Disorder, Conduct Disorder, Anxiety Disorders, Depression, Autism Spectrum Disorder
Clinical Description
Attention-Deficit/Hyperactivity Disorder is a neurodevelopmental disorder characterized by persistent patterns of inattention and/or hyperactivity-impulsivity that interfere with functioning or development. Symptoms must be present before age 12, occur in multiple settings, and cause clinically significant impairment.
ICD-10 Coding Specifications
F90.0 - Attention-deficit hyperactivity disorder, predominantly inattentive type
F90.1 - Attention-deficit hyperactivity disorder, predominantly hyperactive type
F90.2 - Attention-deficit hyperactivity disorder, combined type
F90.8 - Attention-deficit hyperactivity disorder, other type
F90.9 - Attention-deficit hyperactivity disorder, unspecified type
Diagnostic Criteria
Inattention Symptoms (6+ required for children, 5+ for adolescents/adults):
Often fails to give close attention to details or makes careless mistakes
Often has difficulty sustaining attention in tasks or play activities
Often does not seem to listen when spoken to directly
Often does not follow through on instructions and fails to finish tasks
Often has difficulty organizing tasks and activities
Often avoids, dislikes, or is reluctant to engage in tasks requiring sustained mental effort
Often loses things necessary for tasks or activities
Is often easily distracted by extraneous stimuli
Is often forgetful in daily activities
Hyperactivity-Impulsivity Symptoms (6+ required for children, 5+ for adolescents/adults):
Hyperactivity:
Often fidgets with or taps hands or feet or squirms in seat
Often leaves seat in situations when remaining seated is expected
Often runs about or climbs in situations where it is inappropriate
Often unable to play or engage in leisure activities quietly
Is often "on the go," acting as if "driven by a motor"
Often talks excessively
Impulsivity:
Often blurts out answers before questions have been completed
Often has difficulty waiting their turn
Often interrupts or intrudes on others
Additional Criteria:
Several symptoms present before age 12 (but not necessarily impairing)
Symptoms present in 2+ settings (home, school, work)
Clear evidence of clinically significant impairment
Symptoms not better explained by another mental disorder
Presentation Types
Type | Criteria | Clinical Features |
Predominantly Inattentive (F90.0) | 6+ inattention symptoms, <6 hyperactivity-impulsivity symptoms | Difficulty focusing, disorganization, forgetfulness |
Predominantly Hyperactive-Impulsive (F90.1) | 6+ hyperactivity-impulsivity symptoms, <6 inattention symptoms | Restlessness, impulsivity, difficulty sitting still |
Combined Type (F90.2) | 6+ symptoms from both categories | Most common presentation, mixed symptoms |
Differential Diagnosis
Condition | Distinguishing Features | ICD-10 Code |
Autism Spectrum Disorder | Restricted interests, repetitive behaviors, social communication deficits | F84.0 |
Intellectual Disability | Significantly below-average intellectual functioning | F70-F79 |
Specific Learning Disorder | Academic difficulties in specific domains without generalized attention problems | F81.x |
Oppositional Defiant Disorder | Defiant, hostile behavior toward authority figures | F91.3 |
Conduct Disorder | Violation of basic rights of others or social norms | F91.x |
Anxiety Disorders | Anxiety-driven inattention and restlessness | F40-F41 |
Bipolar Disorder | Episodic mood disturbances with periods of normalcy | F31.x |
Substance Use Disorders | Symptoms related to substance intoxication/withdrawal | F10-F19 |
Transdiagnostic Considerations
ADHD is part of the neurodevelopmental disorder spectrum and frequently co-occurs with other conditions. Several neuropsychological constructs are involved. In particular, executive functioning deficits are central to ADHD and impact multiple life domains. Treatment often requires addressing comorbid conditions and environmental factors.
Assessment Tools
Validated Screening & Assessment Instruments
Instrument | Description | Age Range | Scoring |
WHO-developed screening for adult ADHD | 18+ years | Score cutoffs for likelihood of ADHD | |
Comprehensive ADHD assessment with parent, teacher, and self-report forms | 6-18 years | T-scores: <60: Average 60-64: Slightly Elevated 65-69: Elevated ≥70: Very Elevated | |
Brief screening tool for ADHD and comorbidities | 6-12 years | Symptom count and impairment ratings | |
Strengths and Weaknesses of ADHD Symptoms and Normal Behavior Scale (SWAN) | Bidirectional (strengths and weaknesses) DSM-based screening and monitoring tool with parent, caregiver, and teacher forms | 5-18 years | Comparison to population with metrics of internal consistency |
Comprehensive behavioral assessment | 2-21 years | T-scores with clinical significance levels | |
Objective measures of sustained attention, hyperactivity, and impulsivity administered through digital platform | 6+ years | Various indices of attention and response control |
Treatment Approaches
Evidence-Based Psychosocial Interventions
Behavioral interventions are the foundation of ADHD treatment, particularly for children. The combination of medication and behavioral therapy typically provides optimal outcomes.
Approach | Level of Evidence | Key Components | Age Group |
Behavioral Parent Training | Strong | Contingency management, positive reinforcement, consistent consequences | Children/Adolescents |
Behavioral Classroom Management | Strong | Token economies, daily report cards, environmental modifications | School-age |
Cognitive Behavioral Therapy | Moderate | Problem-solving skills, self-monitoring, cognitive restructuring | Adolescents/Adults |
Social Skills Training | Moderate | Peer interaction skills, communication training, group activities | Children/Adolescents |
Executive Function Training | Emerging | Working memory training, organization skills, planning strategies | All ages |
Mindfulness-Based Interventions | Emerging | Attention training, emotional regulation, present-moment awareness | Adolescents/Adults |
Evidence-Based Medication Options
These tables include only a sample of available formulations. Please provide recommendations according to your patient’s specific clinical factors.
Stimulant medications are first-line treatment for ADHD, with non-stimulants as alternatives for those who cannot tolerate or do not respond to stimulants.
Stimulant Medications
Medication | Duration | Starting Dose | Target Dose | Notes |
Methylphenidate-Based | ||||
Ritalin (immediate-release) | 3-4 hours | 5 mg BID | 10-20 mg BID-TID | Multiple daily doses required |
Ritalin LA | 8 hours | 10-20 mg daily | 20-60 mg daily | Once daily dosing |
Concerta | 12 hours | 18-36 mg daily | 36-72 mg daily | OROS delivery system |
Daytrana (patch) | 9 hours | 10 mg patch | 15-30 mg patch | Transdermal option |
Amphetamine-Based | ||||
Adderall (immediate-release) | 4-6 hours | 5 mg BID | 10-20 mg BID | Mixed amphetamine salts |
Adderall XR | 10-12 hours | 10-20 mg daily | 20-60 mg daily | Extended-release capsule |
Vyvanse | 12-14 hours | 20-30 mg daily | 50-70 mg daily | Prodrug, abuse-deterrent |
Non-Stimulant Medications
Medication | Mechanism | Starting Dose | Target Dose | Notes |
Atomoxetine (Strattera) | NRI | 0.5 mg/kg/day | 1.2-1.8 mg/kg/day | 24-hour coverage, no abuse potential |
Guanfacine XR (Intuniv) | Alpha-2A agonist | 1 mg daily | 1-4 mg daily | Helpful for hyperactivity, sleep issues |
Clonidine XR (Kapvay) | Alpha-2 agonist | 0.1 mg daily | 0.1-0.4 mg daily | Sedating, helpful for aggression |
Viloxazine (Qelbree) | NRI | Age/weight based | Age/weight based | Newer option, once daily |
Medication Management Considerations
Monitoring Parameters:
Height and weight (growth charts)
Blood pressure and heart rate
Sleep patterns and appetite
Mood and behavioral changes
Academic/occupational functioning
Side effect assessment
Common Side Effects:
Appetite suppression and weight loss
Sleep difficulties
Mood changes (irritability, sadness)
Growth suppression (temporary)
Cardiovascular effects (mild)
Rebound symptoms
Multimodal Treatment Approach
Children (6-11 years):
Behavioral parent training (first-line)
Behavioral classroom interventions
Medication if behavioral interventions are insufficient
School accommodations and supports
Adolescents (12-17 years):
Combination of medication and behavioral therapy
Academic accommodations and support
Driver education and safety planning
Transition planning for adulthood
Adults (18+ years):
Medication management
CBT focused on organization and time management
Workplace accommodations
Treatment of comorbid conditions
Addressing Common Treatment Challenges
Challenge | Strategies |
Medication adherence | Long-acting formulations, reminder systems, address stigma |
Academic underachievement | IEP/504 plans, tutoring, study skills training |
Social difficulties | Social skills training, peer support groups |
Emotional dysregulation | DBT skills, mindfulness, emotion regulation strategies |
Substance use risk | Psychoeducation, monitoring, non-stimulant options |
Driving safety | Graduated licensing, medication timing, safety education |
Educational and Workplace Considerations
School-Based Interventions
Section 504 Accommodations:
Extended time on tests and assignments
Preferential seating (front of class, away from distractions)
Break tasks into smaller segments
Use of assistive technology
Modified homework assignments
Alternative testing formats
Individualized Education Program (IEP):
May qualify under "Other Health Impairment" category
Requires documented adverse impact on educational performance
Includes specialized instruction and related services
Annual goals and progress monitoring
Classroom Strategies:
Clear, consistent routines and expectations
Visual schedules and reminders
Frequent feedback and reinforcement
Movement breaks and fidget tools
Minimize distractions in environment
Workplace Accommodations
Common ADA Accommodations:
Flexible scheduling and break times
Quiet workspace or noise-canceling headphones
Written instructions and task lists
Extended deadlines for projects
Technology aids (reminder apps, organizers)
Regular check-ins with supervisor
Documentation, Coding, and Reimbursement
ICD-10 Coding Tips
F90 requires a 4th character to specify presentation type
Document specific symptoms from both inattention and hyperactivity-impulsivity criteria
Include age of onset (must be before age 12)
Specify settings where impairment occurs
Document functional impairment in academic, social, or occupational domains
Consider coding comorbid conditions separately
Medical Necessity Documentation Language
Example statements to support medical necessity:
"Patient exhibits [X] symptoms of inattention and [X] symptoms of hyperactivity-impulsivity present since age [X]"
"ADHD symptoms cause significant impairment in academic performance as evidenced by [specific examples]"
"Functional impairment documented across multiple settings including home and school/work"
"Previous interventions attempted include [list] with limited success"
"Current [rating scale] scores indicate [severity level] ADHD symptoms requiring treatment"
Other Documentation Requirements for Reimbursement
Comprehensive developmental history
Multi-informant assessment (parent, teacher, self-report)
Evidence of symptoms before age 12
Documentation of impairment in 2+ settings
Differential diagnosis ruling out other conditions
Treatment plan with specific, measurable goals
Regular monitoring and adjustment documentation
Specific Payer Considerations
Payer | Typical Reimbursement | Authorization Requirements | Special Considerations |
Medicare | Limited coverage for adults | Prior auth may be required | Focus on functional impairment |
Medicaid | Generally covered | Varies by state | May require specific provider types |
Private Insurance | Usually covered | May require prior auth for medications | Step therapy requirements common |
School Districts | Assessment and services under IDEA/504 | Referral process required | Free appropriate public education |
Patient Education Resources
Handouts for Patients and Families
Digital Resources
Recommended Apps:
Forest: Focus and productivity timer
Todoist: Task management and organization
Brain Focus: Pomodoro technique timer
Habitica: Gamified habit tracking
Freedom: Website and app blocker
Online Communities:
Psychoeducational Talking Points
ADHD as a neurodevelopmental difference: ADHD involves differences in brain structure and function, particularly in areas responsible for executive functioning, attention regulation, and impulse control. Neuroimaging studies show differences in the prefrontal cortex, basal ganglia, and cerebellum. These brain differences explain why people with ADHD struggle with tasks that others may find automatic, like sustained attention, organization, and impulse control. Understanding ADHD as a neurobiological condition helps reduce blame and stigma while supporting the need for appropriate accommodations and treatment.
Executive functioning deficits and their real-world impact: Executive functions are the mental skills that include working memory, flexible thinking, and self-control. ADHD primarily affects these "CEO" functions of the brain. This explains why someone with ADHD might be intelligent and capable but struggle with seemingly simple tasks like remembering instructions, managing time, or organizing materials. These aren't character flaws or laziness but genuine neurological challenges that require specific strategies and sometimes accommodations to overcome.
The role of dopamine and motivation: ADHD brains have differences in dopamine pathways, which affect motivation, reward processing, and the ability to sustain attention on less immediately rewarding tasks. This explains why people with ADHD can hyperfocus on interesting activities but struggle with routine or boring tasks. It's not about willpower or caring less; it's about neurochemical differences that make some activities feel unrewarding or even physically uncomfortable to pursue.
Medication myths and realities: ADHD medications don't "cure" ADHD but help normalize brain chemistry to improve attention, reduce impulsivity, and enhance executive functioning. Stimulant medications are among the most well-researched and effective treatments in all of medicine, with decades of safety data. They don't change personality or turn children into "zombies" when properly prescribed and monitored. The goal is to help the person access their natural abilities and potential by reducing the neurological barriers that ADHD creates.
Strengths and positive aspects of ADHD: While ADHD presents challenges, it also comes with potential strengths including creativity, out-of-the-box thinking, high energy, resilience, hyperfocus abilities, and entrepreneurial thinking. Many successful individuals in various fields have ADHD. Treatment isn't about eliminating all ADHD traits but about managing the problematic aspects while preserving and channeling the positive characteristics. Understanding this helps maintain self-esteem and motivation for treatment.
Lifelong nature and changing presentations: ADHD is a lifelong condition, though symptoms and their impact change across development. Hyperactivity often decreases with age while attention and executive functioning challenges may persist or become more apparent as life demands increase. Adult ADHD may look different from childhood ADHD, often presenting as chronic disorganization, procrastination, relationship difficulties, or career underachievement. Recognizing these changing presentations helps with appropriate treatment adjustments throughout life.
Reference Materials and Further Reading
Clinical Practice Guidelines
Emerging Research
Precision medicine approaches to ADHD treatment
Buitelaar J, Bölte S, Brandeis D, Caye A, Christmann N, Cortese S, Coghill D, Faraone SV, Franke B, Gleitz M, Greven CU, Kooij S, Leffa DT, Rommelse N, Newcorn JH, Polanczyk GV, Rohde LA, Simonoff E, Stein M, Vitiello B, Yazgan Y, Roesler M, Doepfner M, Banaschewski T. Toward Precision Medicine in ADHD. Front Behav Neurosci. 2022 Jul 6;16:900981. doi: 10.3389/fnbeh.2022.900981. PMID: 35874653; PMCID: PMC9299434.
Digital therapeutics and technology-based interventions
Kollins SH, DeLoss DJ, Cañadas E, Lutz J, Findling RL, Keefe RSE, Epstein JN, Cutler AJ, Faraone SV. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit Health. 2020 Apr;2(4):e168-e178. doi: 10.1016/S2589-7500(20)30017-0. Epub 2020 Feb 24. PMID: 33334505.
Adult ADHD recognition and treatment
Young S, Bramham J, Gray K, Rose E. The experience of receiving a diagnosis and treatment of ADHD in adulthood: a qualitative study of clinically referred patients using interpretative phenomenological analysis. J Atten Disord. 2008 Jan;11(4):493-503. doi: 10.1177/1087054707305172. Epub 2007 Aug 21. PMID: 17712173.
Neuroplasticity and cognitive training
Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW, Holtmann M, Santosh P, Stevenson J, Stringaris A, Zuddas A, Sonuga-Barke EJ; European ADHD Guidelines Group (EAGG). Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):164-74. doi: 10.1016/j.jaac.2014.12.010. Epub 2014 Dec 29. Erratum in: J Am Acad Child Adolesc Psychiatry. 2015 May;54(5):433. PMID: 25721181; PMCID: PMC4382075.
Inflammation and ADHD
Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a risk factor for attention deficit hyperactivity disorder. Pharmacol Biochem Behav. 2019 Jul;182:22-34. doi: 10.1016/j.pbb.2019.05.005. Epub 2019 May 16. PMID: 31103523; PMCID: PMC6855401.
Specialized Books for Clinicians
"Taking Charge of ADHD: The Complete, Authoritative Guide for Parents" by Russell A. Barkley
The gold standard resource for understanding ADHD in children and adolescents. Dr. Barkley, a leading ADHD researcher, provides comprehensive coverage of assessment, treatment, and management strategies. Essential for clinicians working with families affected by ADHD.
"ADHD in Adults: What the Science Says" by Russell A. Barkley, Kevin R. Murphy, and Mariellen Fischer
The definitive clinical guide to adult ADHD, covering assessment, diagnosis, and treatment. Provides detailed protocols for evaluating adults and addresses the unique challenges of ADHD across the lifespan.
“ADHD 2.0: New Science and Essential Strategies for Thriving with Distraction - from Childhood through Adulthood” by Edward M. Hallowell and John J. Ratey
A strengths-oriented overview of ADHD featuring insights from cutting-edge research.
"Attention-Deficit Hyperactivity Disorder: A Clinical Workbook" by Russell A. Barkley and Kevin R. Murphy
A comprehensive clinical workbook providing assessment forms, rating scales, and treatment protocols. Includes reproducible materials and step-by-step guidance for clinical practice.
"Smart but Scattered: The Revolutionary 'Executive Skills' Approach to Helping Kids Reach Their Potential" by Peg Dawson and Richard Guare
Focuses on executive functioning deficits in ADHD and provides practical strategies for building these crucial skills in children and adolescents. Excellent resource for clinicians, parents, and educators.
"The ADHD Effect on Marriage: Understand and Rebuild Your Relationship in Six Steps" by Melissa Orlov
Addresses the impact of ADHD on relationships and provides practical strategies for couples. Essential reading for clinicians treating adults with ADHD and relationship difficulties.
Last Updated: June 2025
More from Allia